How has Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital/hybrid savvy?
How will Indian Pharma cope with the possibility of another lockdown and F2F meeting restrictions in view of the rising Omicron wave?
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
